Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2016
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Ophthalmics Partnering 2010 to 2016 provides the full collection of Ophthalmics disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Ophthalmics partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Ophthalmics partnering agreement structure

Ophthalmics partnering contract documents

Top Ophthalmics deals by value

Most active Ophthalmics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Ophthalmics deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Ophthalmics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2010. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.

Report scope

Global Ophthalmics Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Ophthalmics trends and structure of deals entered into by leading companies worldwide.

Global Ophthalmics Partnering 2010 to 2016 includes:

Trends in Ophthalmics dealmaking in the biopharma industry since 2010

Analysis of Ophthalmics deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Ophthalmics deal contract documents

Comprehensive access to over 3500 Ophthalmics deal records

The leading Ophthalmics deals by value since 2010

Most active Ophthalmics dealmakers since 2010

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

In Global Ophthalmics Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Ophthalmics Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Ophthalmics Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Ophthalmics deal trends since 2010

Access Ophthalmics deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Ophthalmics partner companies

Comprehensive access to over 750 links to actual Ophthalmics deals entered into by the world's biopharma companies

Indepth review of Ophthalmics deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Ophthalmics opportunities

Uncover companies actively partnering Ophthalmics opportunities

Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for Ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 - Leading Ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in Ophthalmics partnering
4.3. List of most active dealmakers in Ophthalmics
4.4. Top Ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory
5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Ophthalmics therapeutic target

Appendices
Appendix 1 - Directory of Ophthalmics deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Ophthalmics deals by deal type 2010 to 2016
Appendix 3 - Directory of Ophthalmics deals by stage of development 2010 to 2016
Appendix 4 - Directory of Ophthalmics deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Ophthalmics partnering since 2010
Figure 2: Ophthalmics partnering by deal type since 2010
Figure 3: Ophthalmics partnering by industry sector since 2010
Figure 4: Ophthalmics partnering by stage of development since 2010
Figure 5: Ophthalmics partnering by technology type since 2010
Figure 6: Ophthalmics partnering by indication since 2010
Figure 7: Ophthalmics deals with a headline value
Figure 8: Ophthalmics deals with upfront payment values
Figure 9: Ophthalmics deals with milestone payment
Figure 10: Ophthalmics deals with royalty rates
Figure 11: Active Ophthalmics dealmaking activity- 2010 to 2016
Figure 12: Top Ophthalmics deals by value since 2010
  • Ophthalmology Drug Development Pipeline Review, 2016
    Published: 01-Dec-2016        Price: US 3995 Onwards        Pages: 633
    Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmology, there are currently no curative therapies for any of these indications. In particular, there are strong unmet needs within age-related macular degeneration and glaucoma, which can lead to blindness if not adequately treated. Although there......
  • Global Dry Eye Syndrome Drug Market Research Report 2016
    Published: 30-Nov-2016        Price: US 2900 Onwards        Pages: 102
    Notes: Production, means the output of Dry Eye Syndrome Drug Revenue, means the sales value of Dry Eye Syndrome Drug This report studies Dry Eye Syndrome Drug in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Allergan - Novartis - Santen - Shire - Otsuka ......
  • Global Conjunctivitis Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 30-Nov-2016        Price: US 3480 Onwards        Pages: 118
    Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.Conjunctivitis is more commonly referred to as pink eye. The whites of the eyes appear pink or red when the conjunctiva (the transparent membrane which lines part of the eyeball) becomes inflamed or infected......
  • Global Optic Neuritis Market Research Report 2016
    Published: 17-Nov-2016        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Optic Neuritis Revenue, means the sales value of Optic Neuritis This report studies Optic Neuritis in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Sicor Societa' Italiana Corticosteroidi S.R.L - Allergan Pharmaceuticals Ireland......
  • Macular Edema - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 63
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2016, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged bl......
  • Diabetic Retinopathy - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 237
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposi......
  • Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 136
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Dry (Atrophic) Macular Degeneration (Ophthalmology) pipeline landscape.Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred o......
  • Retinal Vein Occlusion - Pipeline Review, H2 2016
    Published: 09-Nov-2016        Price: US 2000 Onwards        Pages: 76
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2016, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclero......
  • Global Assistive Technologies for Visual Impairment Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Nov-2016        Price: US 3480 Onwards        Pages: 117
    Assistive Technologies for Visual Impairment is an umbrella term that includes assistive, adaptive, and rehabilitative devices for people with Visual Impairment and also includes the process used in selecting, locating, and using them. Scope of the Report: This report focuses on the Assistive Technologies for Visual Impairment in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market bas......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs